Structure and functions of angiotensinogen

Hong Lu1,2, Lisa A Cassis3, Craig W Vander Kooi4 and Alan Daugherty1,2,3

Angiotensinogen (AGT) is the sole precursor of all angiotensin peptides. Although AGT is generally considered as a passive substrate of the renin–angiotensin system, there is accumulating evidence that the regulation and functions of AGT are intricate. Understanding the diversity of AGT properties has been enhanced by protein structural analysis and animal studies. In addition to whole-body genetic deletion, AGT can be regulated in vivo by cell-specific procedures, adeno-associated viral approaches and antisense oligonucleotides. Indeed, the availability of these multiple manipulations of AGT in vivo has provided new insights into the multifaceted roles of AGT. In this review, the combination of structural and functional studies is highlighted to focus on the increasing recognition that AGT exerts effects beyond being a sole provider of angiotensin peptides.

Hypertension Research (2016) 39, 492–500; doi:10.1038/hr.2016.17; published online 18 February 2016

Keywords: angiotensinogen; atherosclerosis; LoxP-Cre; obesity; structure

INTRODUCTION

The renin–angiotensin system (RAS) is pivotal to the regulation of blood pressure and homeostasis of water and sodium through actions of angiotensin II (AngII). Recently many other bioactive angiotensin peptides have been identified (Figure 1). The RAS is now recognized as a major regulator for a wide range of physiological and pathophysiological functions. Angiotensinogen (AGT) is the only precursor of all angiotensin peptides. Human AGT has 485 amino acids, including a 33 amino-acid signal peptide. The 10 N-terminal amino acids are cleaved by renin to provide angiotensin I (AngI), which is the source for an array of active angiotensin peptides (Figure 1). The removal of AngI leaves a protein termed des(AngI)AGT. Despite des(AngI)AGT being 98% of the parent protein, its biological properties and fate are largely unknown. Indeed, even fundamental questions such as the relative concentrations of intact AGT vs. des(AngI)AGT in plasma and tissues have not been determined.

There is increasing acknowledgment that AGT is more than a mere passive substrate for the RAS. Recent studies have provided insights into new roles of AGT in both angiotensin peptide-dependent and -independent manners. We have discussed many biological properties of AGT in a recent review article. The present review will primarily focus on structural analysis and in vivo manipulations of AGT.

STRUCTURE–FUNCTION OF ANGIOTENSINOGEN PROTEIN

Structural model of AGT for AngI release

AGT is a member of the non-inhibitory serpin (serine protease inhibitor) superfamily. Other members of the serpin family include alpha1 antitrypsin, alpha1 antichymotrypsin and antithrombin III. The N-terminus of AGT, encoding AngI, represents a unique extension compared with other serpin family members.

An initial model of AGT structure was developed by sequence alignment with ovalbumin, which is also an non-inhibitory serpin. The major tenets of this proposed structural model was confirmed when AGT was crystallized and the structure was resolved for recombinant non-glycosylated mouse, rat and human proteins. Non-glycosylated AGT has a molecular weight of 53 kDa and can be present in states of up to 75 kDa based on the extent of glycosylation. The variability of these glycosylation sites contributes to the difficulty in obtaining sufficient quality crystals to enable X-ray diffraction.

The cleavage of AGT by renin is the rate-limiting step to release AngI. The initial structural study implicates that renin cleavage efficacy can be facilitated by interactions with domains beyond the N-terminal amino acids of AGT. This speculation is partially based on the lower Km for AGT interactions with renin (2.6 μM), compared with a chimera of alpha1 antitrypsin and the 17 N-terminal amino acids of AGT interacting with renin (47.5 μM). This Km is also lower than the isolated N-terminal tetradecapeptide of AGT. This initial analysis suggests that there are angiotensin-dependent roles of other regions beyond the N-terminus of AGT.

Renin cleavage of AGT also exhibits species specificity. For example, human AGT cannot be readily cleaved by mouse renin. This has been demonstrated in mice carrying human AGT transgene that requires co-expression of human renin to facilitate AngII production. It is assumed that the presence of Leu11-Tyr12 in mouse AGT vs. Val11-Ile12 in human AGT leads to impaired enzymatic kinetics of mouse renin to cleave human AGT. However, no studies
have directly determined whether replacing Leu11-Tyr12 in mouse AGT to Val11-Ile12 would impair mouse renin cleavage in vivo.

Conserved Cys18-Cys138 disulfide bond in AngII-dependent functions

The initial structural analysis has noted that cysteines at positions 18 and 138 of human AGT (Cys18-Cys137 in mice) have the potential to form an intermolecular disulfide bond that is conserved across species. A subsequent study has confirmed the presence of this disulfide bond. The AGT protein is secreted with the disulfide bond, which can be reduced by an unknown mechanism. Resolution of the crystal structure of AGT protein found that the renin cleavage site of AGT was buried in the N-terminus of the AGT N-terminal tail. The conformational rearrangement that represents conserved residues across species. Sequence conversation of AngII across species. Blue color denotes conserved residues across species.

Figure 1 The renin–angiotensin cascade. Angiotensinogen is the substrate, and renin is its direct enzyme to generate all downstream angiotensin peptides. Numbers in parenthesis represent residue numbered starting from the N-terminus. "aa" denotes "amino acid".

oxidized vs. reduced forms of AGT in a more precise quantitative method.

Potentially functional conserved sequences in the core serpin domain of AGT

Analysis of conservation in AGT provides significant insight into functionally important regions of the protein. For example, the eight amino acids encoding AngII are highly conserved across a wide range of species (Figure 2). In addition to the highly conserved AngII-encoding sequence, the core hydrophobic residues that stabilize the protein structure are also highly conserved. Additionally, comparison of sequence conservation of AGT protein has revealed interesting aspects on both the distal and proximal renin interacting surfaces of the protein. des(AngI)AGT encodes the core serpin domain, which contains other significant regions of conserved residues as mapped on the surface of the protein using Consurf, a web server for surface-mapping phylogenetic information (Figure 3). One conserved region is on the face proximal to AngI sequence, which is shown to directly contact renin. Although it is anticipated to contribute to the AngII-dependent functions of AGT, there is no direct experimental evidence for this hypothesis. On the face distal to the renin-binding surface, two highly conserved regions are also present. Because of the remote location, this face is unlikely to contribute to AngII release or AGT–renin interaction.

A few studies demonstrate that AGT exerts AngII-independent effects and des(AngI)AGT has direct biological properties. These include effects on renal function, blood–brain barrier, angiogenesis, adipose expansion and liver steatosis. The functional determination of these conserved regions and cross-species differences in vivo will provide insights into understanding the structural contributions of AT1 and AT2 receptors and biological functions dependent and independent of AngII release.

| Species            | Sequence of AngII |
|--------------------|-------------------|
| Human              | DRVYIHPF          |
| Orangutan          | DRVYIHPF          |
| Mouse              | DRVYIHPF          |
| Rat                | DRVYIHPF          |
| Cow                | DRVYIHPF          |
| Horse              | DRVYVHPF          |
| Guinea Pig         | DRVYVHPF          |
| Chicken            | DRVYIHPF          |
| Three-toed Amphiumas | DRVYVHPF      |
| Alligator           | DRVYIHPF         |
| Horn Fly            | DRVYIHPF          |
| Zebra Fish         | NRVYIHPF          |
| Silver Sea Bream    | NRVYIHPF          |
FUNCTIONAL CONSEQUENCES OF GENETIC OR PHARMACOLOGICAL MANIPULATIONS OF AGT

Global deficiency or reduction of AGT through genetic manipulations

Mouse models with genetic manipulations of AGT are summarized in Table 1. Whole-body AGT-deficient mice were developed in the 1990s by two research groups. These mice have low neonatal survival rate, impaired growth and renal development (Figure 4) and low blood pressure. Impaired growth is manifested by low birth body weight and stunted body weight gain during the development to adulthood, compared with their wild-type littermates. Whole-body deficiency of AGT leads to impaired body weight gain irrespective of normal or a fat-enriched diet feeding, less fat mass and higher locomotor activity in mice; an interesting contrast is that mice with human AGT and renin transgenes also have less body weight gain compared with their wild-type controls, although these mice have increased AGT and renin expression, resulting in increases of AngII productions. Therefore, the lean phenotype in these two mouse models cannot be explained by changes of AngII production.

As severe health issues in whole-body AGT-deficient mice hamper its use, AGT floxed mice were developed to determine its biological and pathophysiological functions. In an initially developed AGT floxed mice, the neo cassette in the targeting gene was not removed. Inclusion of the neo cassette resulted in whole-body reductions of AGT but did not compromise neonatal survival rate, general growth and kidney development. Therefore, this is an AGT hypomorphic (hypo AGT) mouse model. Hypo AGT mice in an low-density lipoprotein (LDL) receptor (LDLr)–/– background have lower blood pressure and nearly ablated atherosclerotic lesions, compared with their wild-type littermates. These two effects are expected because high blood pressure and atherosclerosis are two well-recognized AngII-dependent effects in hypercholesterolemic mice. Unexpectedly, although hypo AGT mice have comparable body weight as their wild-type littermates when fed a normal laboratory diet, these mice have diminished body weight gain and liver steatosis when they are fed a diet that has a fat content (42% kcal from saturated fat) similar to the average dietary composition of Western nations.9

Cell-specific depletion of AGT using Cre-LoxP technique

Cre-LoxP technique has been used extensively in the past decade to determine cell-specific effects of genes. In earlier studies to understand AGT biological properties, this technique was applied to mice with human AGT transgene or both human AGT and renin transgenes. In mice expressing human AGT transgene, depletion of human AGT specifically in the brain leads to ablated blood pressure responses to human renin infusion into brain. In mice with both human AGT and renin transgene expression specifically in the brain, brain AngII is increased, but peripheral AngII is reduced. These mice have lower body weight (Table 1), higher sympathetic nervous activity and increased energy expenditure. Increased metabolic rates in these mice are attenuated by blockade of beta-adrenergic activity or increases of peripheral AngII level. It is worth noting that these mice are not healthy with one-third of mice dying prior to weaning, possibly owing to deficiency in retaining sodium. Findings from these studies infer that AngII production in the brain regulates functions in peripheral organs.

Recently, four research groups have reported AGT floxed mice with cell-specific deletion (Table 1). AGT is expressed in adipocytes, and findings from in vitro studies have implicated that AGT derived from this cell type promotes obesity and cardiovascular disease. To directly determine the role of adipocyte-derived AGT, AGT floxed mice were bred to those expressing Cre under the control of the AP2 promoter. An initial study found that adipocyte-specific deletion of AGT reduced its plasma concentrations by 24–28%, accompanied by reductions of blood pressure. These changes occurred in the absence of effects on body weight, fat mass, adipocyte size or glucose homeostasis. A subsequent study determined effects of adipocyte-specific AGT deletion on blood pressure in mice fed a diet containing either low fat (10% kcal) or high fat (60% kcal). Plasma AGT concentrations were unchanged in these mice, but systolic blood pressure was decreased, compared with their wild-type controls. As with mice fed a normal laboratory diet, body weight was not influenced in mice fed the 60% fat diet but modestly increased in mice fed the 10% kcal fat diet. Another study in adipocyte-specific AGT-deleted mice failed to demonstrate effects on body weight when...
Table 1 Genetic manipulations of angiotensinogen in mice

| Genotype                  | Neonatal survival | Kidney | Heart | Plasma AGT | Blood pressure | Atherosclerosis | Body weight gain | Liver steatosis | References |
|---------------------------|-------------------|--------|-------|------------|----------------|-----------------|------------------|----------------|------------|
| AGT−/−                    | Fed ND/WD         | Fed ND | Fed ND | NA         | ↓              | NA              | Fed ND and J Fed HFD | NA             | 16,17,21-24 |
| HypoAGT                   |                   |        | Fed WD | ↓↓         | ↓              | ↓               |                  |                |            |
| Renal AGT−/−              |                   |        |        | NA         | ↔              | ↔               |                  |                | 25         |
| AdipAGT−/−                |                   |        |        | NA         | ↑              | NA              | Fed ND/HFD       | NA             | 18         |
| AdipAGT−/− ↔               |                   |        |        | NA         | ↔              | ↔               |                  |                | 9, 25, 26   |
| Human AGT                 |                   |        |        | NA         | ↔              | ↔               |                  |                | 9, 25, 26, 33 |

Abbreviations: AdipAGT, adipocyte-specific expression of AGT; AdipAGT−/−, adipocyte-specific AGT−/− mice; AGT, angiotensinogen; BMC, bone marrow cell; hepAGT−/−, hepatocyte-specific AGT−/− mice; HFD, high-fat diet (60% kcal); hyp AGT, AGT hypomorphic mice; LFD, low-fat diet (10% kcal); WD, Western diet (42-45% kcal).

In contrast to depleting a gene using the Cre-LoxP technique, Adeno-associated viral expression of AGT has been considered the major systemic source. Hepatocyte-derived AGT is the major functional component, with all studies noting pronounced decreases in blood pressure. Of note, profound effects of hepatocyte-specific AGT inhibition on plasma AGT concentrations and blood pressure have also been reported in a rat model of hypertension using an siRNA approach.

In addition to reductions of blood pressure, two studies have reported less atherosclerosis and diminished body weight gain and liver steatosis induced by a Western (42% kcal) diet in hepatocyte-specific AGT−/− mice that were also deficient in LDL receptors. One study, which showed ~50% reductions of plasma AGT concentrations, failed to demonstrate hepatocyte-specific AGT−/− mice having changes in body weight in mice fed a high fat (60% kcal) diet. The importance of hepatocyte-derived AGT has also been demonstrated by comparing to mice with renal-specific AGT deficiency (Table 1). Renal deficiency of AGT has no discernable effects on obesity and blood pressure in mice.

Adenoviral expression of AGT

In contrast to depleting a gene using the Cre-LoxP technique, AAV expression is a facile approach for repopulating or overexpressing a specific gene or its mutations in either cell-specific or systemic manner. In mice with hepatocyte-specific deficiency of AGT, two
studies have reported repopulation of manipulated AGT gene through a single i.p. injection of AAVs that contain a hepatocyte-specific promoter thyroxine-binding globulin. In a study described earlier, mutation of the Cys18-Cys137 disulfide bond did not affect renin cleavage of AGT to release AngI and did not regulate production and functions of AngII in hepatocyte-specific AGT-deficient mice. In a subsequent study, AAVs containing either mouse full-length AGT or des(AngI)AGT were injected into mice with hepatocyte-specific deficiency of AGT. This approach in mice lacking circulating AGT resulted in restoration of either full-length AGT that could be cleaved into AngI and des(AngI)AGT or des(AngI)AGT alone without increasing AngII. Repopulation of full-length AGT increased AngII production, blood pressure, atherosclerosis, diet-induced body weight gain and liver steatosis, whereas repopulation of des(AngI)AGT did not affect AngII production and atherosclerosis but increased diet-induced body weight gain and liver steatosis. These studies provide direct evidence that AGT contributes to diet-induced obesity and liver steatosis through des(AngI)AGT-mediated mechanisms, which are independent of AngII.

**Antisense Oligonucleotides (ASO) against AGT**

ASO against AGT targets AGT mRNA, leading to its degradation, thereby reducing AGT protein production. Three recent studies have reported that mouse AGT ASO inhibits AGT mRNA in major organs such as the liver, kidney and adipose tissues. Inhibition of mouse AGT mRNA synthesis attenuates kidney dysfunction in mouse models with polycystic kidney disease and reduces blood pressure, atherosclerosis and obesity in hypercholesterolemic mice. These findings are consistent with phenotypes observed in mice with AGT deletions using genetic approaches. Compared with mice manipulated genetically, there are several benefits of using AGT ASO. First, this pharmacological approach can be used in adult mice, thereby avoiding potential impairments on development and normal growth. Second, this approach can be used to study established pathological conditions. For example, in LDL receptor−/− mice fed a Western diet for 12 weeks, atherosclerosis and obesity were established prior to pharmacological intervention. Administration of AGT ASO into mice with these established diseases attenuated further progression of atherosclerosis and regressed preexisting obesity. Most importantly, and of clinical relevance, ASO is a potential approach for treating human diseases. Two pharmaceutical companies, Alnylam and Ionis, have announced development of ASO for reducing AGT synthesis in humans for preeclampsia and resistant hypertension, respectively.

**COMPARISONS OF GENETIC AND PHARMACOLOGICAL INHIBITIONS BETWEEN AGT AND OTHER CLASSIC RENIN–ANGIOTENSIN COMPONENTS**

Many components of the RAS have been studied in whole-body deficient mice of several components of the system. Consistent with phenotypes observed in mice with whole-body deficiency of AGT, global deficiency of renin or angiotensin-converting enzyme (ACE) or co-deficiency of AT1a and AT1b receptors also leads to low neonatal survival rate, impaired growth and renal development and low blood pressure. Global deficiency of all these components also have ‘beneficial’ effects on obesity as reported in the literature. However, their severe growth and health impairments compromise this phenotype interpretation. Table 2 summarizes the phenotypes reported in mice with genetic deletions of renin, ACE or AngII receptors. As outlined in both Tables 1 and 2, it is clear that mice with whole-body deficiency of a key member in the RAS have severe phenotypes such as impairments of kidney and heart development, general growth and low blood pressure that are attributed to either depleted AngII production (whole-body deficiency of AGT, renin or ACE) or interrupted AngII–AT1 receptor interaction (AT1a and AT1b co-deficiency), thereby being AngII-dependent phenotypes.

Genetic mouse models of AGT, renin or ACE deficiency have lower body weight that may be attributed to developmental impairment. In contrast, pharmacological inhibition of the renin angiotensin components in adult mice does not affect development and body growth. In an unbiased literature search using the key words ‘renin inhibition’, ‘aliskiren’, ‘angiotensin-converting enzyme’, ‘ACE inhibitor’, ‘AT1 receptor blockers’, ‘AT1 receptor antagonists’, combined with ‘body weight’ and ‘mouse’, 85 studies determined effects of pharmacological renin–angiotensin inhibition on body weight in mice. The majority of studies report that renin–angiotensin inhibition does not change body weight in adult mice. A small number of manuscripts (total 17 of 85; renin inhibition: 2 of 11; ACE inhibition: 4 of 25 and AT1 receptor blockade: 11 of 49) report renin–angiotensin inhibition attenuating

---

**Table 2 Genetic manipulations of renin, ACE or AngII receptors in mice**

| Genotype         | Neonatal survival | Kidney             | Heart             | Blood pressure | Atherosclerosis | Body weight | Liver steatosis | References |
|------------------|-------------------|--------------------|-------------------|----------------|-----------------|-------------|----------------|------------|
| Renin−/−         | ↓                 | Hydronephrosis     | NA                | ↓              | NA              | ↓ Fed ND/HFD| ↓ Fat absorption| 48,51      |
| BMC renin−/−     | NA                | NA                 | NA                | ←             | ←              | ←          | ←              | NA 36      |
| Human renin      | NA                | NA                 | NA                | ←             | ←              | ↑ Fed ND   | ↑ at 60 weeks | 53-55      |
| ACE−/−           | ↓                 | Hydronephrosis     | NA                | ↓              | NA              | ↑          | ←              | 22,49,52   |
| BMC ACE−/−       | NA                | NA                 | NA                | ←             | ←              | ↑          | ←              | 56         |
| AT1aR−/−         | ↓ or ←           | ↑ or ←             | ↑ or ←            | ↑              | ↑               | ↑          | ↑              | 34,57-61   |
| AT1bR−/−         | ←                 | ←                 | ←                 | ←              | ←               | NA         | ↑              | 50,62,63   |
| AT1aR−/− × AT1bR−/− | ↓              | Hydronephrosis     | Cardiomyopathy    | ↓              | NA              | ↑ Fed ND   | NA              | 50,62,64   |
| AT2R−/−          | ←                 | ←                 | ←                 | ←              | ←               | Fed ND/HFD | ←              | 34,62,65,66|
| AT1aR−/− × AT2R−/− | ←              | Glomerular atrophy | Cardiomyopathy    | ↓ (MAP)        | NA              | Fed ND    | NA              | 62,64      |
| AT1bR−/− × AT2R−/− | ←              | ←                 | ←                 | ← (MAP)        | NA              | ↑         | NA              | 62,64      |
| AT1aR−/− × AT1bR−/− × | ↓            | Hydronephrosis     | Cardiomyopathy    | ↓ (MAP)        | NA              | ↑ Fed ND   | NA              | 62,64      |
| AT2R−/−          | ←                 | ←                 | ←                 | ←              | ←               | ←         | ←              | 62,64      |

Abbreviations: ACE, angiotensin-converting enzyme; BMC, bone marrow cell; HFD, high-fat diet; MAP, mean arterial pressure; NA, not available; ND, normal diet.
body weight gain. However, body weight changes in most studies are either modest during certain intervals or attributed to reduced food intake. Table 3 summarizes effects of renin inhibition on body weight in mice. Among 11 articles that have studied effects of renin inhibition on body weight, 2 articles report that aliskiren reduces body weight gain. In one study, aliskiren (30 mg kg day$^{-1}$ for 6 weeks) leads to reduced body weight gain of $<3\%$ in a few intervals during 6 weeks of normal or a high-fat diet feeding in C57BL/6 mice. The other study reports that aliskiren (50 mg kg day$^{-1}$ for 14 days) reduces body weight gain by approximately 10% in a type 2 diabetic mouse model, KK-Ay. In addition to the modest changes of body weight in body weight gain by approximately 10% in a type 2 diabetic mouse leads to reduced body weight gain of 6 weeks of normal or a high-fat diet feeding in C57BL/6 mice. The weight gain. In one study, aliskiren (50 mg kg day$^{-1}$) reduces body weight gain. 2 articles report that aliskiren reduces body weight gain by AGT inhibition, renin inhibition reduces blood pressure and atherosclerosis; however, it has no effect on diet-induced obesity. These findings are due to that these studies, it is worth noting that high dose of aliskiren induces skin necrosis, resulting in impairment of health. Therefore, it is important to record whether reductions of body weight in mice administered aliskiren is related to skin necrosis or other health concerns. Overall, although genetic deletion of renin, ACE or AngII receptors leads to dramatic phenotypes on body weight, these have not been consistently mimicked by pharmacological inhibition of these same RAS components in adult animals. This dichotomy is possibly due to phenotypes in whole-body deficient mice being attributed to developmental defects rather than reductions in RAS activity.

In contrast to extensive studies on other components of the RAS, effects of AGT inhibition have not been explored owing to the lack of pharmacological agents that directly target this protein. The lack of efforts in developing an AGT inhibitor may be attributable to the common thought that it would provide no additional benefits over the three existing modes of RAS inhibitors. In contrast to this thought, a recent study has demonstrated that inhibition of AGT using ASO not only reduces blood pressure and atherosclerosis but also diminishes body weight gain. Both inhibition of AGT and renin diminishes generation of downstream angiotensin peptides. ASO against AGT reduces intact AGT and des(AngI)AGT, leading to reductions of total AGT, whereas renin inhibition increases intact AGT and reduces des(AngI)AGT with no changes of total plasma AGT. In agreement with AGT inhibition, renin inhibition reduces blood pressure and atherosclerosis; however, it has no effect on diet-induced obesity. These findings support the concept that AGT has both AngII-dependent and -independent functions.

Collectively, in contrast to inconsistencies of body weight and its related phenotypes between whole-body genetic manipulations and pharmacological inhibitions of renin, ACE or AT1 receptors, AGT functions are consistently defined by cell-specific genetic manipulations, AAV administration and pharmacological inhibition using ASOs.

### ASSOCIATIONS OF AGT POLYMORPHISMS WITH PATHOPHYSIOLOGICAL FUNCTIONS IN HUMANS

Mapping single-nucleotide polymorphisms is extensively used in genome-wide association studies to identify functional variations in DNA sequences. Two missense mutations, T174M and M235T, and multiple single-nucleotide polymorphisms, including A(-6)G and A(-20)C in the promoter region of the human AGT gene, have been comprehensively studied. These polymorphisms, for example, M235T and A(-6), are in close linkage disequilibrium. M235T is associated with plasma AGT concentrations. Although this polymorphism has been reported to be associated with essential hypertension in many studies, others do not observe this association.

In contrast to inconsistencies of body weight and its related phenotypes between whole-body genetic manipulations and pharmacological inhibitions of renin, ACE or AT1 receptors, AGT functions are consistently defined by cell-specific genetic manipulations, AAV administration and pharmacological inhibition using ASOs.

| Mouse strain | Aliskiren mg kg day$^{-1}$ (duration) | Diet | Food intake | Blood pressure | Atherosclerosis | Body weight gain | Liver steatosis | References |
|--------------|-------------------------------------|------|-------------|----------------|----------------|-----------------|-----------------|------------|
| KK-Ay (F)    | 50 (2 weeks)                        | Normal | NA          | ↓              | NA             | ↓ -10%          | NA              | 68         |
| C57BL/6 (M)  | 50 (6 weeks)                        | 10% kcal from fat | ↔ NA         | NA             | ↓ -4%          | NA              | 67         |
|              |                                     | 45% kcal from fat | ↔ NA         | NA             | ↓ -4%          | NA              | 67         |
|              | 3, 10 (2 weeks)                     | NA    | ↔ NA        | NA             | ↔             | NA              | NA              | 69         |
|              | 25, 50 (2 weeks)                    | NA    | ↓ NA        | NA             | ↔             | NA              | NA              | 69         |
|              | 50 (6 weeks)$^a$                    | 50% kcal from fat | ↔ ↓ NA      | NA             | ↔             | NA              | NA              | 70         |
| C57BL/6 (M) and STZ | 20                          | NA    | ↔ NA        | NA             | ↔             | NA              | NA              | 71         |
| Ldlr$^{-/-}$ (M) | 2.5, 25 or 50 (12 weeks)            | 42% kcal from fat | ↓ ↓ ↔        | ↔             | ↔             | ↔               | 36         |
|              | 2.5, 12.5 or 25 (12 weeks)          | 42% kcal from fat | ↓ ↓ ↔        | ↔             | ↔             | ↔               | 38         |
|              | 12.5 (12 weeks)                     | 42% kcal from fat | ↓ ↓ ↔        | ↔             | ↔             | ↔               | 38         |
| db/db (M)    | 3 (6 weeks)                         | Normal | NA          | ↔ NA          | NA             | NA              | NA              | 72         |
|              | 6, 12, 25 (6 weeks)                 | Normal | NA          | ↓ NA          | NA             | NA              | NA              | 73         |
|              | 25 (12 weeks)                       | NA    | NA          | NA             | ↔             | ↔               | ↔               | 74         |

Abbreviations: F, female; M, male; NA, not available; STZ, streptozotocin.

$^a$Started high-fat diet 2 weeks prior to administration of aliskiren.

---

**Table 3** Effects of renin inhibition by aliskiren on multiple pathological conditions in mice

---

**Structure and functions of AGT**

H Lu et al

Hypertension Research

497
findings, combined with findings that adipocyte-specific deficiency of AGT has no effects on body weight gain as demonstrated in mice,\textsuperscript{23,28,29} implicate that adipose-derived AGT is not a major contributor to AGT-mediated body weight changes.

**CONCLUSIONS AND PERSPECTIVES**

There is accumulating evidence that AGT has functions in addition to serving as the essential source of angiotensin peptides. The significance of exploring AGT structure and biological functions will be enhanced by evolving pharmacological strategies, as the protein is now a therapeutic target of two companies (Alnylam and Ionis), who have announced development of ASOs for reducing AGT synthesis in humans. Despite AGT being the only source of the entire angiotensin peptides, many fundamental questions of AGT biological properties still need to be answered: (1) Which conserved residues of AGT contribute to AngII-dependent and -independent effects? (2) What are the molecular mechanisms by which AGT regulates obesity and liver steatosis? Are these direct effects or indirect effects through a specific pathway or multiple signaling pathways? (3) How and why does AGT produced in hepatocytes contribute to functions in other tissues and organs such as the kidney and adipose tissues? and (4) Do AGT and des(Ang)AGT have their own receptors?

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

Our research work is supported by a grant from the National Institutes of Health (HL107319 to Alan Daugherty) and a pilot grant to Hong Lu by an Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20 GM103527.

---

1. Wu C, Lu H, Cassis LA, Daugherty A. Molecular and pathophysiologica features of angiotensinogen: a mini review. N Am J Med Sci (Bosten) 2011; 4: 183–190.
2. Streetfied-James RM, Williamson D, Pike RN, Teaksbury D, Carell RW, Coughlin PB. Angiotensinogen cleavage by renin: importance of a structurally constrained N-termi-nus. FEBS Lett 1998; 436: 267–270.
3. Zhou A, Carnell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, Stein PE, Broughton Pipkin F, Read RJ. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010; 468: 108–111.
4. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Sae MS, Takahashi S, Hatake T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993; 268: 11617–11621.
5. Yang G, Merrill DC, Thompson MW, Carney CL, Granwehr BP, Schlager G, Robillard JE, Cassis LA. Deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012; 302: R244–R251.
6. Fukamizu S, Takimoto K, Fukuoka S, Yagami K, Murakami K, Ishii M, Kominami S, Inagami T, Cassis LA. Hypercholesterolemia stimulates release of angiotensinogen peptide synthesis and contributes to atherosclerosis through the AT1A receptor. J Biol Chem 2004; 279: 1189–1196.
7. Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A. Impaired blood-brain barrier function in angiotensinogen-deicient mice. Mol Biol Cell 2014; 25: 43–47.
8. Wu C, Xu Y, Lu H, Howatt DA, Balkrishnan A, Monkrogan JH, Koo CW, Cassis LA, Wang JA, Daugherty A. Cys18-Cys13 disulfide bond in mouse angiotensinogen does not affect AngII-dependent functions in vivo. Hypertension 2015; 65: 800–805.
9. Glaser F, Pupko T, Paz I, Bell RE, Bchor-Shental D, Martz E, Ben-Tal ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 2003; 19: 163–164.
10. Lu H, Wu C, Howatt DA, Balkrishnan A, Monkrogan JH, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A. Angiotensinogen exerts effects independent of angiotensin II. Arterioscler Thromb Vasc Biol 2016; 36: 256–265.
11. Bouquet C, Lamande S, Brand M, Cassis JM, Jullienne B, Faure G, Griscelli F, Opolon P, Connaught E, Perricaudet M, Corvol P. Suppression of angioiogenes, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther 2006; 14: 175–182.
12. Corvol P, Lamande N, Cruz A, Cellerier J, Cassis JM. Inhibition of angiogenesis: a new function for angiotensinogen and desangiotensin Iangiotensinogen. Curr Hypertens Rep 2003; 5: 149–154.
13. Vincent F, Bonnin P, Clernessy M, Contreres JD, Lamande N, Cassis JM, Villar J, Hainaud P, Tobelman G, Corvol P, Dupuy E. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009; 69: 2853–2860.
14. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
15. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
16. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Coffman TM, Maeda N, Smithies O. Control of blood pressure by angiotensinogen. J Biol Chem 2006; 281: 20921–20929.
17. Kim S, Tsuru S, Massiera F, Watanabe T, Shiota N, Taniguchi K, Ueno Y, Tanimoto K, Fukamizu A, Murakami K, Ishii M, Kominami S, Inagami T, Cassis LA. Hypercholesterolemia stimulates release of angiotensinogen peptide synthesis and contributes to atherosclerosis through the AT1A receptor. J Biol Chem 2006; 281: 20921–20929.
18. Bogousslavsky J, Dashe H, Ferreira P, Liu T. In vivo angiogenesis analysis in the chick chorioallantoic membrane. J Mol Med (Berl) 2007; 85: 451–460.
19. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
20. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
21. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
22. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
23. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
24. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
25. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
26. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
27. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
28. Tanimoto K, Sugiyama F, Goto Y, Ishida H, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypertension. J Biol Chem 2014; 289: 31334–31337.
29. Kim HS, Kehe JH, Klucken KM, Haagrman J, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2733–2739.
30. Mccrindle Ps, Hsu H, Fukamizu A, Miyake H, Murakami K, Ishii M, Kominami S, Inagami T, Cassis LA. Hypercholesterolemia stimulates release of angiotensinogen peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004; 110: 3894–3897.
Lu H, Cassis LA, Daugherty A. Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets 2007; 8: 1181–1189.

Lu H, Rateri DL, Feldman DL, Charnigo RJ Jr, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 97–102.

Daugherty A, Lu H, Rateri DL, Cassis LA. Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol 2008; 3: 625–636.

Lu H, Balakrishnan A, Howat DA, Wu C, Charnigo R, Liu G, Cassis LA, Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolemia-induced atherosclerosis. Br J Pharmacol 2012; 165: 2000–2008.

Lu H, Wu C, Howat DA, Balakrishnan A, Charnigo RJ Jr, Cassis LA, Daugherty A. Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice. J Nutr Biochem 2013; 24: 49–53.

Sinnayah P, Lazariegues E, Sakai K, Sharma RV, Sigmond CD, Dawson RL. Genetic ablation of angiotensinogen in the subfornical organ of the brain prevents the central angiotensinergic pressor response. Circ Res 2006; 99: 1125–1131.

Cassis LA, Saye J, peach MJ. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988; 11: 596–591.

Boustany CM, Bharadwaj K, Daughtery A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004; 287: R943–R949.

Cassis LA, Police SB, Yannirkos F, Thachter SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008; 10: 93–98.

Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs without the need for ramosa results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res 2014; 37: 405–412.

Saigusa T, Dang Y, Mullick AE, Yeh ST, Zile MR, Baicu CF, Bell PD. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. J N u t r B i o c h e m 2013; 99: 1235.

Kato N, Sugiyama T, Morita H, Kurihara H, Furukawa T, Isshiki T, Sato T, et al. Angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism. PLoS ONE 2013; 8: e61849.

Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009; 158: 771–778.

Iwai M, Kanno H, Tomono Y, Inaba S, Senba I, Furuno M, Mago M, Horuchi M. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471–1481.

Jeunemaitre X, Munnich A, Robberecht P, Bernardi M. Dynamic rearrangement of mechanically-mobilized renal mesenchyme reveals an inflammasome-like dysfunction of renin inhibitor. Arterioscler Thromb Vasc Biol 2009; 29: 1858–1863.

Franz ED, Penna-de-Carvalho A, Batista Tde M, Aguilà MB, Mandarin-de-Lacerda CA, Araujo JB, Lamas CS, et al. Renin-angiotensin system-induced hypertension and insulin resistance in C57BL/6J mice. Meta S y n d R e l R e l a t 2014; 12: 191–201.

Thomas CM, Yong QC, Sequea R, Chandel N, Feldman DL, Baker KM, Kumar R. Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Ci n C l i n (Lond) 2013; 124: 529–541.

Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nishimori I, Ogawa H, Kim-Mitsuya S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010; 28: 1554–1565.

Kang YS, Lee MS, Hong HK, Hyun YH, Cha DJ, Ko GJ, Kim SH, Lee JE, Han HY, Cha DR. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 2011; 26: 1194–1204.

Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther 2011; 25: 505–515.

Jain S, Vinukonda G, Fiering SN, Kumar A. A haplotype of human angiotensinogen gene containing -217A increases blood pressure in transgenic mice compared with -217G. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1849–R1857.

Jeunemaitre X, Loustot F, Kotelevetz YV, Lutton RF, Williams CS, Charu A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell 1997; 1: 169–180.

Jeunemaitre X, Leduf F, Bataglia S, Guillerme MT, Courbon D, Dumont C, Darmon O, Khanban D, Cummings JH, Rohrer D. Gain-of-function mutations in the renin-angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet 1997; 96: 63–77.

Ito H, Harada S, Shimamoto T, Sato T, Kitamura A, Sankai T, Tanigawa T, Iida M, Kikuchi T, Angiotensin II AT1 receptor variants, sodium intake and hypertension among non-drinking, lean and men. J Hypertens 2000; 18: 1197–1206.

Pan WH, Chen JW, Fann C, Jou WS, Yu SY. Linkage analysis with candidate genes: the Taiwan young-onset hypertension genetic study. Hum Genet 2000; 107: 210–217.

Rankinen T, Gagnon J, Perusse L, Chagnon YC, Rice T, Leon AS, Skiriner JS, Wilmore JH, Rao DC, Bouchard C. AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study. Am J Physiol Heart Circ Physiol 2000; 279: H368-H374.

Brand E, Chate lain N, Keavney B, Cauifield M, Citterio L, Connell J, Grobbe D, Schmidt S, Schunkert H, Schuster H, Sharma AM, Soubrier F. Evaluation of the angiotensinogen locus in human essential hypertension: a European study. Hypertension 1998; 31: 725–729.

Bengtsson K, Orho-Melander M, Lindblad U, Melander O, Bog-Hansen E, Ranstam J, Rastam L, Groop PM. Polymorphism in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project. J Hypertens 1999; 17: 1569–1575.

Taittoren L, Uhari M, Kontula K, Kainulainen K, Miettinen H, Turbinen J, Nuutinen M. Angiotensin converting enzyme insertion/deletion polymorphism, angiotensinogen gene polymorphisms, family history of hypertension, and childhood blood pressure. Am J Hypertens 1999; 12: 858–866.

Kato N, Sugiyama T, Morita H, Kurihara H, Furukawa T, Ishitiki T, Sato T, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and angiotensinogen gene polymorphisms with relation to hypertension in the Japanese. J Hypertens 2000; 18: 1025–1032.
85 Larson N, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans. Hypertension 2000; 35: 1297–1300.

86 Province MA, Boerwinkle E, Chakravarti A, Cooper R, Fornage M, Leppert M, Risch N, Ranade K. Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program. National Heart, Lung and Blood Institute. J Hypertens 2000; 18: 867–876.

87 Wang L, Zhang B, Li M, Li C, Liu J, Liu Y, Wang Z, Zhou J, Wen S. Association between single-nucleotide polymorphisms in six hypertensive candidate genes and hypertension among northern Han Chinese individuals. Hypertens Res 2014; 37: 1068–1074.

88 Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka T, Tanaka T, Fujikura J, Ebihara K, Hosoda K, Katsurada A, Ohishi N, Urushihara M, Kogure H, Morimoto N, Kawazoe T, Naitoh M, Okada M, Sakaue H, Suzuki S, Nakao K. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010; 23: 425–431.

89 Engeli S, Bohrke J, Ganzelniak K, Jankie J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356–362.

90 Oberbach A, Schlichting N, Neuhaus J, Kulmich Y, Lehmann S, Heinrich M, Dietrich A, Mohr FW, von Bergen M, Baumann S. Establishing a reliable multiple reaction monitoring-based method for the quantification of obesity-associated comorbidities in serum and adipose tissue requires intensive clinical validation. J Proteome Res 2014; 13: 5784–5800.

91 Van Harmelen V, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 2000; 24: 673–678.

92 Demura M, Demura Y, Takeda Y, Saijo K. Dynamic regulation of the angiotensinogen gene by DNA methylation, which is influenced by various stimuli experienced in daily life. Hypertens Res 2015; 38: 519–527.

93 Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000; 8: 337–341.

94 Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Ann J Physiol 1997; 273: 236–242.

95 Kršková K, Filipič P, Zíka N, Olszanecki R, Korbut R, Gajdosechová L, Zorad S. Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARgamma). J Physiol Pharmacol 2011; 62: 403–410.